A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inh

Brief description of study

This research study aims to find out if two medicines, livmoniplimab (a special drug used to boost the body's ability to fight liver cancer) and budigalimab (improves the body's defense system against liver cancer), can help people with a certain type of liver cancer called HCC (Hepatocellular Carcinoma) when other treatments haven't worked well. The study will test different doses of these medicines to see which one works best and is safe for patients. Some patients will receive these medicines, while others will get different treatments that doctors commonly use for this cancer. People with liver cancer will be part of this study, and their health will be closely watched to see how they respond to the medicines and if there are any side effects.

Clinical Study Identifier: s23-00133
Principal Investigator: Nina Beri.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.